Guggenheim Capital’s Idexx Laboratories IDXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$10.7M Buy
20,242
+2,818
+16% +$1.58M 0.07% 278
2026
Q1
$9.79M Sell
17,424
-3,918
-18% -$2.51M 0.08% 272
2025
Q4
$14.4M Buy
21,342
+1,402
+7% +$955K 0.1% 197
2025
Q3
$12.7M Sell
19,940
-1,229
-6% -$746K 0.09% 221
2025
Q2
$11.4M Buy
21,169
+3,577
+20% +$1.71M 0.09% 226
2025
Q1
$7.39M Sell
17,592
-5,091
-22% -$2.21M 0.07% 315
2024
Q4
$9.38M Sell
22,683
-122
-0.5% -$53.5K 0.08% 264
2024
Q3
$11.5M Sell
22,805
-2,603
-10% -$1.26M 0.08% 265
2024
Q2
$12.4M Sell
25,408
-4,169
-14% -$2.09M 0.09% 240
2024
Q1
$16M Buy
29,577
+994
+3% +$543K 0.11% 178
2023
Q4
$15.9M Buy
28,583
+412
+1% +$193K 0.12% 177
2023
Q3
$12.3M Buy
28,171
+5,039
+22% +$2.51M 0.11% 212
2023
Q2
$11.6M Buy
23,132
+2,305
+11% +$1.1M 0.09% 240
2023
Q1
$10.4M Sell
20,827
-554
-3% -$265K 0.09% 272
2022
Q4
$8.72M Buy
21,381
+270
+1% +$105K 0.08% 328
2022
Q3
$6.88M Buy
21,111
+517
+3% +$190K 0.06% 387
2022
Q2
$7.22M Sell
20,594
-2,759
-12% -$1.13M 0.06% 406
2022
Q1
$12.8M Sell
23,353
-5,337
-19% -$2.81M 0.08% 312
2021
Q4
$18.9M Sell
28,690
-282
-1% -$177K 0.1% 225
2021
Q3
$18M Sell
28,972
-1,126
-4% -$757K 0.11% 204
2021
Q2
$19M Buy
30,098
+3,943
+15% +$2.18M 0.11% 202
2021
Q1
$12.8M Sell
26,155
-3,422
-12% -$1.71M 0.08% 286
2020
Q4
$14.8M Buy
29,577
+4,352
+17% +$1.95M 0.09% 218
2020
Q3
$9.92M Sell
25,225
-2,753
-10% -$1.02M 0.07% 283
2020
Q2
$9.24M Buy
27,978
+6,079
+28% +$1.76M 0.07% 290
2020
Q1
$5.3M Sell
21,899
-6,901
-24% -$1.8M 0.05% 418
2019
Q4
$7.52M Sell
28,800
-6,548
-19% -$1.73M 0.06% 429
2019
Q3
$9.61M Buy
35,348
+10,020
+40% +$2.79M 0.08% 327
2019
Q2
$6.97M Sell
25,328
-1,785
-7% -$440K 0.06% 434
2019
Q1
$6.06M Sell
27,113
-8,869
-25% -$1.83M 0.05% 514
2018
Q4
$6.69M Sell
35,982
-14,776
-29% -$3.03M 0.06% 420
2018
Q3
$12.7M Buy
50,758
+14,907
+42% +$3.62M 0.08% 269
2018
Q2
$7.81M Sell
35,851
-312,188
-90% -$64.3M 0.05% 447
2018
Q1
$66.6M Sell
348,039
-55,865
-14% -$10.3M 0.16% 159
2017
Q4
$63.2M Sell
403,904
-109,396
-21% -$17.2M 0.15% 198
2017
Q3
$79.8M Sell
513,300
-4,423
-0.9% -$699K 0.19% 76
2017
Q2
$83.6M Sell
517,723
-14,444
-3% -$2.35M 0.22% 60
2017
Q1
$82.3M Buy
532,167
+413,933
+350% +$57.1M 0.22% 54
2016
Q4
$13.9M Buy
118,234
+98,136
+488% +$11.2M 0.04% 575
2016
Q3
$2.27M Sell
20,098
-2,199
-10% -$232K 0.01% 1543
2016
Q2
$2.07M Buy
22,297
+1,085
+5% +$93.2K 0.01% 1544
2016
Q1
$1.66M Sell
21,212
-16,118
-43% -$1.16M 0.01% 1695
2015
Q4
$2.72M Sell
37,330
-133,755
-78% -$9.54M 0.01% 1392
2015
Q3
$12.7M Sell
171,085
-2,379
-1% -$170K 0.04% 665
2015
Q2
$11.1M Sell
173,464
-15,634
-8% -$1.08M 0.03% 790
2015
Q1
$14.6M Sell
189,098
-13,076
-6% -$1.02M 0.03% 716
2014
Q4
$15M Buy
202,174
+154,010
+320% +$10.8M 0.04% 703
2014
Q3
$2.84M Buy
48,164
+8,358
+21% +$528K 0.01% 1516
2014
Q2
$2.66M Sell
39,806
-16,902
-30% -$1.07M 0.01% 1575
2014
Q1
$3.44M Buy
56,708
+39,272
+225% +$2.34M 0.01% 1371
2013
Q4
$927K Sell
17,436
-5,604
-24% -$295K ﹤0.01% 2279
2013
Q3
$1.15M Buy
23,040
+16,748
+266% +$805K ﹤0.01% 2017
2013
Q2
$283K Buy
+6,292
New +$275K ﹤0.01% 2636

Other funds holding IDXX

Guggenheim Capital's IDXX Position: Q2 2026 in Review

Guggenheim Capital increased its Idexx Laboratories (IDXX) stake by 16% in Q2 2026, buying an estimated $1.58M and bringing the position to 20,242 shares worth $10.7M. The position accounts for 0.07% of the portfolio, ranked #278.

Guggenheim Capital first reported a position in IDXX in Q2 2013 and has held it in 53 quarters since. The position peaked at $83.6M in Q2 2017. 1,300 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Guggenheim Capital held 20,242 shares of Idexx Laboratories worth $10.7M as of Q2 2026.
  • Guggenheim Capital bought 2,818 Idexx Laboratories shares in Q2 2026, an estimated $1.58M.
  • Idexx Laboratories made up 0.07% of Guggenheim Capital's portfolio in Q2 2026, its #278 holding.
  • Guggenheim Capital first reported a position in Idexx Laboratories in Q2 2013 and has held it in 53 quarters since.
  • Guggenheim Capital's Idexx Laboratories position peaked at $83.6M in Q2 2017.
  • 1,300 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.